Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Psychopharmacology (Berl) ; 166(2): 163-7, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12545333

RESUMEN

RATIONALE: Chronic treatment with benzodiazepines induces tolerance to most of their pharmacological effects. The best-studied neurochemical correlation to this phenomenon involves GABAergic adaptive changes. However, some compensation by excitatory neurotransmission could also be postulated. OBJECTIVE: The aim of this work was to investigate the effect of chronic treatment with benzodiazepines on several parameters of hippocampal glutamatergic neurotransmission. METHODS: Rats were injected (IP) with a single dose or daily doses (21 days) of 1 mg/kg lorazepam (LZ) or vehicle. Thirty minutes after the last dose, animals were killed and parameters were measured in the dissected hippocampi. We determined one presynaptic parameter, in vitro glutamate release induced by a 60 mM K(+) stimulus. [(3)H]MK-801 binding to postsynaptic NMDA receptors and the NMDA-stimulated efflux of cGMP were also evaluated. RESULTS: While no changes were observed in any of the parameters after a single dose of the drug, we found an increase of 206% in in vitro glutamate release in chronically treated animals [two-way ANOVA: F(1,16)=6.22], together with an increment of 103% in the NMDA-stimulated cGMP efflux [two-way ANOVA: F(1,18)=14.05]. No changes either in K(D) or in B(max) values for [(3)H]MK-801 binding to hippocampal membranes were observed. CONCLUSIONS: Taken together, these changes strongly suggest that a compensatory increase in the glutamatergic response develops in the hippocampus during chronic treatment with LZ. Our findings might indicate a contribution of glutamatergic mechanisms to the tolerance to hippocampal-mediated effects of LZ, such as amnesic and anticonvulsant activities.


Asunto(s)
Ansiolíticos/farmacología , Ácido Glutámico/metabolismo , Hipocampo/efectos de los fármacos , Lorazepam/farmacología , Transmisión Sináptica/efectos de los fármacos , Adaptación Fisiológica , Animales , GMP Cíclico/biosíntesis , Maleato de Dizocilpina/farmacología , Hipocampo/metabolismo , Masculino , N-Metilaspartato/farmacología , Potasio/farmacología , Ratas , Ratas Wistar , Receptores de N-Metil-D-Aspartato/análisis , Ácido gamma-Aminobutírico/metabolismo
2.
Exp Biol Med (Maywood) ; 226(6): 612-7, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11395934

RESUMEN

The effects of Wallerian degeneration of the peripheral sympathetic neurons projecting to the hypothalamus on the mechanism of interaction between prolactin and substance P (SP) were examined. The effects of superior cervical ganglionectomy (SCGx) on SP content in various hypothalamic regions and in the hypophysis were evaluated in control and hyperprolactinemic rats. Male rats that received pituitary transplants at the age of 5 days and age-matched sham-operated controls were used. Pituitary grafting significantly increased circulating values of prolactin, as did SCGx. In hyperprolactinemic rats, SCGx partially decreased plasma prolactin levels. Neonatal hyperprolactinemia decreased SP content in the anterior (AH) and posterior (PH) hypothalamus and in the median eminence (ME), but increased it in the mediobasal hypothalamus (MBH). Acute SCGx significantly increased SP in the MBH, PH, and ME. SCGx in hyperprolactinemic animals further increased SP content in MBH. In the ME and Ah, SCGx in pituitary grafted rats decreased SP content as compared with the controls. In the pituitary gland (PG), SCGx only decreased SP content in hyperprolactinemic, but not in control rats. An interaction between peripheral nor-adrenergic neurons and prolactin to regulate SP within the hypothalamus was positive in the MBH, AH, ME, and PG, but not in the PH. These data indicate the existence of interactive mechanisms between prolactin and the peripheral sympathetic neurons to regulate SP content at the hypothalamic-pituitary axis. Interrelationships between prolactin and SP were also observed.


Asunto(s)
Hiperprolactinemia/metabolismo , Hipotálamo/metabolismo , Hipófisis/metabolismo , Sustancia P/metabolismo , Sistema Nervioso Simpático/metabolismo , Degeneración Walleriana/metabolismo , Animales , Ganglionectomía , Hipotálamo Anterior/metabolismo , Hipotálamo Posterior/metabolismo , Masculino , Neuronas/metabolismo , Prolactina/sangre , Ratas , Ratas Wistar , Ganglio Cervical Superior
3.
Mol Cell Endocrinol ; 172(1-2): 7-12, 2001 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-11165034

RESUMEN

Nitric oxide (NO) affects cyclooxygenase (COX) and lipooxygenase (LOX) activities in several tissues. The aim of this study was to investigate the effect of NO on the AA metabolism in the anterior pituitary. LOX and COX products from anterior pituitaries of Wistar male rats were determined by [14C]-AA radioconversion method. Sodium nitroprusside (NP, 0.5 mM) and DETA NONOate (1 mM), NO donors, decreased 5-hydroxy-5,8,11,14-eicosatetraenoic acid (5-HETE) synthesis (P<0.05), effects that were reversed by hemoglobin. L-arginine also inhibited LOX activity. To the contrary, the inhibition of NO synthase by L-NAME (0.5 mM) or aminoguanidine (0.5 mM) increased 5-HETE production (P<0.05). COX activity was slightly stimulated by NP and L-arginine. However, DETA NONOate induced a stimulation of the synthesis of all prostanoids (P<0.05), this effect being reversed by hemoglobin. Neither NOS inhibitors nor hemoglobin modified basal prostanoids synthesis. These results indicate that NO inhibits LOX activity and stimulates COX activity in the anterior pituitary gland. The inhibition of LOX by NO may be another mechanism involved in the effects of NO on hormone release in the anterior pituitary.


Asunto(s)
Ácido Araquidónico/metabolismo , Óxido Nítrico/fisiología , Adenohipófisis/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Depuradores de Radicales Libres/farmacología , Ácidos Hidroxieicosatetraenoicos/biosíntesis , Lipooxigenasa/efectos de los fármacos , Lipooxigenasa/metabolismo , Masculino , Óxido Nítrico/farmacología , Prostaglandina-Endoperóxido Sintasas/efectos de los fármacos , Prostaglandina-Endoperóxido Sintasas/metabolismo , Ratas , Ratas Wistar
4.
J Endocrinol ; 166(2): 373-80, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10927626

RESUMEN

Substance P (SP) may participate as a paracrine and/or autocrine factor in the regulation of anterior pituitary function. This project studied the effect of TRH on SP content and release from anterior pituitary and the role of SP in TRH-induced prolactin release. TRH (10(-7) M), but not vasoactive intestinal polypeptide (VIP), increased immunoreactive-SP (ir-SP) content and release from male rat anterior pituitary in vitro. An anti-prolactin serum also increased ir-SP release and content. In order to determine whether intrapituitary SP participates in TRH-induced prolactin release, anterior pituitaries were incubated with TRH (10(-7) M) and either WIN 62,577, a specific antagonist of the NK1 receptor, or a specific anti-SP serum. Both WIN 62,577 (10(-8) and 10(-7) M) and the anti-SP serum (1:250) blocked TRH-induced prolactin release. In order to study the interaction between TRH and SP on prolactin release, anterior pituitaries were incubated with either TRH (10(-7) M) or SP, or with both peptides. SP (10(-7) and 10(-6) M) by itself stimulated prolactin release. While 10(-7) M SP did not modify the TRH effect, 10(-6) M SP reduced TRH-stimulated prolactin release. SP (10(-5) M) alone failed to stimulate prolactin release and markedly decreased TRH-induced prolactin release. The present study shows that TRH stimulates ir-SP release and increases ir-SP content in the anterior pituitary. Our data also suggest that SP may act as a modulator of TRH effect on prolactin secretion by a paracrine mechanism.


Asunto(s)
Comunicación Paracrina , Adenohipófisis/metabolismo , Prolactina/metabolismo , Sustancia P/farmacología , Hormona Liberadora de Tirotropina/farmacología , Análisis de Varianza , Androstenos/farmacología , Animales , Bencimidazoles/farmacología , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Sueros Inmunes/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Técnicas de Cultivo de Órganos , Adenohipófisis/química , Adenohipófisis/efectos de los fármacos , Prolactina/análisis , Ratas , Ratas Wistar , Estimulación Química , Sustancia P/análisis , Sustancia P/metabolismo , Hormona Liberadora de Tirotropina/metabolismo , Péptido Intestinal Vasoactivo/farmacología
5.
Eur J Endocrinol ; 143(2): 279-84, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10913949

RESUMEN

OBJECTIVE: In order to determine the mechanism by which nitric oxide (NO) inhibits prolactin release, we investigated the participation of cGMP-dependent cAMP-phosphodiesterases (PDEs) and protein kinase G (PKG) in this effect of NO. METHODS: Anterior pituitary glands of male rats were incubated with inhibitors of PDE and PKG with or without sodium nitroprusside (NP). Prolactin release, and cAMP and cGMP concentrations were determined by RIA. RESULTS AND CONCLUSIONS: The inhibitory effect of NP (0.5 mmol/l) on prolactin release and cAMP concentration was blocked by EHNA (10(-4)mol/l) and HL-725 (10(-4)mol/l), inhibitors of cGMP-stimulated cAMP-PDE (PDE2). 8-Br-cGMP (10(-4) and 10(-3)mol/l), which mimics cGMP as a mediator of NP effects on prolactin release, also decreased cAMP concentration. Zaprinast (10(-4)mol/l), a selective inhibitor of specific cGMP-PDE (PDE5), potentiated the NP effect on cAMP concentration. Rp-8-[(4-chlorophenyl)thio]-cGMP triethylamine (Rp-8-cGMP, 10(-7)-10(-6)mol/l), an inhibitor of PKG, reversed the effect of NP on prolactin release. The present study suggests that several mechanisms are involved in the inhibitory effect of NO on prolactin release. The activation of PDE2 by cGMP may mediate the inhibitory effect of NO on cAMP concentration and therefore on prolactin release. NO-activated PKG may also be participating in the inhibitory effect of NO on prolactin release.


Asunto(s)
Óxido Nítrico/farmacología , Hidrolasas Diéster Fosfóricas/metabolismo , Adenohipófisis/efectos de los fármacos , Adenohipófisis/metabolismo , Prolactina/metabolismo , Proteínas Quinasas/metabolismo , 3',5'-AMP Cíclico Fosfodiesterasas/metabolismo , 3',5'-GMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , 3',5'-GMP Cíclico Fosfodiesterasas/metabolismo , Animales , AMP Cíclico/metabolismo , GMP Cíclico/análogos & derivados , GMP Cíclico/metabolismo , GMP Cíclico/farmacología , Proteínas Quinasas Dependientes de GMP Cíclico , Sinergismo Farmacológico , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Masculino , Nitroprusiato/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Purinonas/farmacología , Ratas , Ratas Wistar
6.
Mol Cell Endocrinol ; 146(1-2): 19-26, 1998 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-10022759

RESUMEN

The effect of nitric oxide donors on intracellular calcium concentration [Ca2+]i was studied in anterior pituitary cells using ratiometric FURA 2 fluorescence measurements. Sodium nitroprusside (NP) induced a transient decrease in [Ca2+]i, after which [Ca2+]i returned to, or even increased over basal values. S-Nitroso glutathione (GSNO) induced a similar decrease. NP also inhibited high [Ca2+]i achieved by depolarization with 25 mM K+. The inhibitory effect of NP was partially blunted by pretreatment with methoxy-verapamil, and in calcium free buffer, and was not altered by thapsigargin. Interestingly, in calcium free buffer there was a significant stimulatory effect of NP, which was partially blunted by thapsigargin. We conclude that NO donors modify [Ca2+]i in anterior pituitary cells. The action is biphasic, with an initial decrease in [Ca2+]i probably related to a decrease of Ca2+ influx through VDCC, and an increase evidenced in calcium free buffer in which the inhibitory component is absent, and partially depends on thapsigargin sensitive calcium stores.


Asunto(s)
Calcio/metabolismo , Donantes de Óxido Nítrico/farmacología , Adenohipófisis/metabolismo , Animales , Tampones (Química) , Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/farmacología , Galopamilo/farmacología , Glutatión/análogos & derivados , Glutatión/farmacología , Líquido Intracelular/metabolismo , Cinética , Masculino , Nitroprusiato/farmacología , Compuestos Nitrosos/farmacología , Potasio/farmacología , Ratas , Ratas Wistar , S-Nitrosoglutatión , Tapsigargina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...